<unk>  is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. In the European Union, the combination is indicated for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/mL) with their current antiretroviral treatment, and when the virus has not developed resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors.
Cabotegravir/rilpivirine
Atazanavir/cobicistat
Atazanavir/ritonavir
Dolutegravir/rilpivirine
Nirmatrelvir/ritonavir
Darunavir/cobicistat
Abacavir/lamivudine
Lamivudine/tenofovir